title: Management of an anti-factor VIII inhibitor occurring during surgical procedure with continuous infusion of Novoseven.
authors.forename: C
authors.initials: C
authors.lastname: Ménart
authors.forename: V
authors.initials: V
authors.lastname: Cognet
authors.forename: P Y
authors.initials: PY
authors.lastname: Petit
authors.forename: D
authors.initials: D
authors.lastname: Massignon
authors.forename: C
authors.initials: C
authors.lastname: Négrier
mesh_terms: D019645:Arthroplasty, Replacement, Knee; D001323:Autoantibodies / Q000276:immunology*; D016063:Blood Loss, Surgical; D004359:Drug Therapy, Combination; D005169:Factor VIII / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use; D015942:Factor VIIa / Q000008:administration & dosage / Q000627:therapeutic use; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006488:Hemostasis, Surgical; D006801:Humans; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D007430:Intraoperative Care; D008297:Male; D011292:Premedication; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D001323:Autoantibodies; D011994:Recombinant Proteins; C078147:F8 protein, human; D005169:Factor VIII; D015942:Factor VIIa